Qfitlia (fitusiran), an siRNA drug to treat the frequency of bleeding episodes in adult and pediatric patients with hemophilia A or B, gets FDA approval.

The firm's Innovance Antithrombin assay is used to monitor antithrombin activity levels in hemophilia patients and aid dosing decisions for a routine prophylaxis.

When Jessamyn Butler would get nosebleeds as a child, her mother would tell her the length of the bleed was normal, no matter ...

With improved market conditions, innovative breakthroughs, and more investor interest, the biotechnology industry is gaining new traction.

The antithrombin assay will support dosing Qfitlia, the sixth Alnylam-discovered RNAi medicine to receive FDA approval.

Despite a haemophilia market bustling with rivals, Qfitlia’s broad label and favourable dosing regimen could give it an upper ...